Current Report Filing (8-k)
March 26 2019 - 5:03PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 26, 2019 (March 20, 2019)
MYOS
RENS TECHNOLOGY INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-53298
|
|
90-0772394
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File
Number)
|
|
(IRS
Employer
Identification
No.)
|
45
Horsehill Road,
Suite
106 Cedar Knolls, New Jersey
|
|
07927
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code
(973) 509-0444
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On
March 20, 2019, MYOS RENS Technology Inc. (the “
Company
”) entered into a Securities Purchase Agreement (the
“
Agreement
”) with a group of accredited investors (the “
Investors
”) providing for the issuance
and sale by the Company of shares of the Company’s common stock, $0.001 par value, at a purchase price of $1.46 per share,
the closing price of the common stock on the Nasdaq Capital Market on such date (the “
Private Placement
”). In
the Private Placement, the Company will issue 1,438,356 shares of common stock to the Investors, including two members of the
Company’s board of directors, for aggregate gross proceeds of $2.1 million, which includes the conversion of $250,000 of
the principal amount of a $1.0 million promissory note previously issued by the Company to its chief executive officer. The Company
intends to use the net proceeds from the Private Placement primarily for working capital, research and development and other general
corporate purposes. The closing of the Offering is expected to occur on or about March 27, 2019, subject to the satisfaction of
customary closing conditions.
The
Agreement provides that the Company will use its commercially reasonable efforts to file a registration statement with the Securities
and Exchange Commission within 45 days from the closing of the Private Placement with respect to the re-sale of the shares issued
in the Private Placement and will use its commercially reasonable efforts to obtain effectiveness of the registration statement
within 90 days of the closing of the Private Placement. The Agreement also contains customary representations and warranties by
the Company.
The
foregoing description of the Agreement is qualified in its entirety by reference to the complete text of the Agreement, filed
hereto as Exhibit 10.1.
Item
3.02. Unregistered Sales of Equity Securities
See
Item 1.01 of this Current Report on Form 8-K, which Item is incorporated by reference into this Item 3.02.
The
securities issued in the Private Placement as described above have not been registered under the Securities Act of 1933, as amended
(the “
Securities Act
”), and such issuances were made pursuant to the exemptions from registration provided
by Section 4 (a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
MYOS RENS TECHNOLOGY, INC.
|
|
|
|
Dated: March 26, 2019
|
By:
|
/s/
Joseph Mannello
|
|
Name:
|
Joseph Mannello
|
|
Title:
|
Chief Executive Officer
|
2
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
MYOS RENS Technology (NASDAQ:MYOS)
Historical Stock Chart
From Jul 2023 to Jul 2024